Find Clinical Trials

Inclusion Criteria * Participants must have at least one measurable lesion per response evaluation criteria in solid tumors. * Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Participants must have a life expectancy of at least 3 months at the time of the first dose. * Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which may include T790M in exon 20. Participants with other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed * Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC. * Group C: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC or ER-low, HER2-negative BC. * Group D: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC per ASCO/CAP criteria, based on the most recently analyzed biopsy or another pathology specimen. * Group E: Participants must have pathologically confirmed locally advanced or metastatic NSCLC, not amenable to treatment in curative intent. Exclusion Criteria * Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology. * Participants with known mutations in EGFR will be excluded (Group A,B and E). * Participants must not have a history of serious recurrent infections. * Participants must not have a history of severe heart disease. * Other protocol-defined Inclusion/Exclusion criteria apply.

Inclusion criteria on or before Time 0 (Time 0 = finerenone initiation date) : * Active registration or continuous enrolment for at least 365 days in the data source before Time 0 (days \[-365, 0\]) * No recorded use of finerenone before Time 0 (days \[-all available, 0\]) * Aged 18 years or older on Time 0 * Diagnosis of T2D at any time on or before Time 0 (days \[-all available, 0\]) * Having a diagnosis code indicating CKD stage 1, 2, 3, 4, or stage unspecified on or before Time 0 (days \[-all available, 0\]) Exclusion criteria on or before Time 0: * Finerenone users who are hospitalized or admitted for an emergency department visit on Time 0 * Type 1 diabetes (T1D) at any time on or before Time * Evidence of end-stage kidney disease (ESKD) at any time on or before Time 0 * A diagnosis of kidney cancer at any time on or before Time 0 * A diagnosis of adrenal insufficiency at any time on or before Time 0 * Evidence of hepatic impairment at any time on or before Time 0 * An eGFR measurement \< 25 mL/min/1.73 m2 on or in the 90 days before Time 0 * Evidence of recent increased serum potassium or hyperkalaemia * Use of a strong CYP3A4 inhibitor on or in the 183 days before Time 0 * Evidence of pregnancy measured on or in the 40 weeks before Time 0

Inclusion Criteria: * Clinical diagnosis of benign thyroid nodules or papillary thyroid carcinoma ; * underwent microwave ablation or thyroidectomy; * ability to understand and cooperate with the survey Exclusion Criteria: * serious primary diseases in the liver, kidney, hematopoietic, or endocrine systems； * a history of mental illness, personality disorders, cognitive impairments, or organic brain disease

Inclusion Criteria: 1. Signed Informed Consent Form (ICF) prior to participation in any study-related activities. 2. Patients aged ≥19 years at the time of signing ICF. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Life expectancy of ≥ 12 weeks. 5. Histologically confirmed TNBC per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria based on local testing on the most recent analyzed biopsy. Triple-negative is defined as \<1% expression for estrogen receptor (ER) and progesterone receptor (PgR) and negative for human epidermal growth factor receptor 2 (HER2) (0-1+ by IHC or 2+ and negative by in situ hybridization \[ISH) test\]. 6. Metastatic disease documented by computerized tomography (CT) scan or magnetic resonance imaging (MRI) that is not amenable to resection with curative intent. 7. Refractory to at least one, and no more than two, prior standard of care chemotherapy regimens for unresectable locally advanced or MBC. PARP inhibitor could have been counted as prior chemotherapy for purposes of study eligibility. 8. All patients must have been previously treated with taxanes regardless of disease stage (adjuvant, neoadjuvant, or advanced), unless contraindicated for a given patient. 9. Measurable or non-measurable, but evaluable disease, as per RECIST v.1.1. Patients with bone-only metastases are also eligible. 10. Brain MRI must be done for patients with suspicion of brain metastases and patient must have stable central nervous system (CNS) disease for at least 4 weeks after local therapy, without neurological symptoms, and off anticonvulsants and steroids (no more than 10mg/day prednisone or its equivalent) for at least 2 weeks before first dose of study treatment. 11. Meet the following organ function requirements: * Hemoglobin ≥ 9 g/dL * ANC ≥ 1500/mm3 * Platelets ≥ 100,000/μL * Bilirubin ≤ 1.5 X IULN or ≤ 3X IULN for patients with documented Gilbert's syndrome * AST and ALT ≤ 2.5 X IULN or ≤ 5 X IULN if known liver metastases * Serum albumin \> 3 g/dL * Creatinine clearance ≥ 60 mL/min or ≥ 30 mL/min as assessed by the Cockcroft-Gault equation * INR/PT and PTT or aPTT ≤ 1.5 X IULN unless patient is currently receiving therapeutic anticoagulant therapy 12. Resolution of all acute AEs of prior anti-cancer therapy to grade 1 as determined by the NCI-CTCAE v.5.0 (except for alopecia or other toxicities not considered a safety risk for the patient at investigator discretion). 13. Male patients and female patients of childbearing potential who engage in heterosexual intercourse must agree to use institution specified method(s) of contraception during treatment with sacituzumab govitecan and for 6months after the last dose. * Required contraception for female of childbearing potential patients using hormonally based method, intrauterine device (IUD), bilateral tubal occlusion, female condom with spermicide should during study period and continue until 6 months after the last dose of latest administered study drug * Required contraception for male patients using abstinence, male condom with spermicide, vasectomy should during study period and continue until 6 months after the last dose of latest administered study drug 14. Patients must have completed all prior cancer treatments at least 2 weeks prior to 1st infusion of study drug including chemotherapy (includes also endocrine treatment), radiotherapy, and major surgery. * Prior anticancer biologic agent must have been completed at least 4 weeks prior to 1st infusion of study drug. Exclusion Criteria: 1. Prior treatment with topoisomerase 1 inhibitors as a free form or as other formulations. 2. Received any prior treatment with a Trop-2-directed ADC. 3. Patients with carcinomatous meningitis. 4. Known hypersensitivity reaction to any investigational or therapeutic compound or their incorporated substances. 5. Patients positive for HIV-1 or -2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease. 6. Have active hepatitis B virus (HBV) (defined as having a positive hepatitis B surface antigen test) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded. 1. Patients who test positive for hepatitis B surface antigen will be excluded. 2. Patients who test positive for hepatitis B core antibody will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease. Patients with positive hepatitis B core antibody but negative viral load by PCR may be eligible if they are being monitored for potential viral reactivation or are willing to start or maintain antiviral treatment during study conduction (as dictated by their local and institutional standard practice or guidelines). A patient with a history of HBV infection and presence of hepatitis B surface antibody may participate in the study. In this last scenario, viral load (HBV DNA) is not mandated. 3. Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require an HCV antibody at screening and will only require HCV RNA by quantitative PCR for confirmation of active disease. 7. Scheduled surgery during the study, other than minor surgery which would not delay study drug (eg, port insertion, tooth extraction, any procedure that requires \< 1-hour general anesthesia. Procedures performed under local or intravenous (IV)/monitored sedation that lasts \< 2 hours are acceptable). 8. Have an active second malignancy. Note: Patients with a history of malignancy that has been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or patients with surgically cured tumors with low risk of recurrence (eg, nonmelanoma skin cancer, histologically confirmed complete excision carcinoma in situ, or similar) are eligible. 9. Known history of clinically significant bleeding, intestinal obstruction, or gastrointestinal perforation within 6 months of study initiation. 10. Active or prior documented inflammatory bowel disease (i.e. Crohn's disease, ulcerative colitis, or a preexisting chronic condition resulting in baseline grade ≥1 diarrhea). 11. Infection requiring antibiotic use within 1 week of 1st infusion of study drug. 12. Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations. 13. Women who are pregnant or lactating. 14. Concomitant participation in other interventional clinical trial. Note: Patients participating in observational studies are eligible. 15. Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the patient's participation in the study 16. Use of other investigational drugs (drugs not marketed for any indication) within 28 days or 5 half-lives (whichever is longer) of first dose of study drug.

Inclusion Criteria: 1. Postpartum 2. ≥ 20 years old with the ability to give informed consent 3. Diagnosis of gestational hypertension, preeclampsia prior to delivery admission, or diagnosed with preeclampsia during delivery admission, as determined by clinical team using the American College of Obstetricians and Gynecologists (ACOG) criteria. 4. English speaking Exclusion Criteria: 1. Individuals who were prescribed an 3-hydroxy-3 methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor prior to or during pregnancy, 2. Known familial hypercholesterolemia or pre-existing hyperlipidemia, specifically Low-density Lipoprotein (LDL) \>190 prior to pregnancy or diagnosis of hyperlipidemia with prescription of HMG-CoA reductase inhibitor prior to delivery, 3. Plan to breastfeed for \>= 6 months, 4. Plan for pregnancy conception in the next 6 months, 5. Incarcerated individuals, 6. Hypertensive diagnosis thought to be secondary to fetal condition, 7. Contraindications to HMG-CoA reductase inhibitor therapy or known hypersensitivity to atorvastatin or any component, 8. Active liver disease (acute hepatitis, chronic active hepatitis, unexplained persistent transaminitis (at least twice upper limit of normal serum transaminases)), 9. History of rhabdomyolysis or myopathy, 10. Human Immunodeficiency Virus (HIV) positivity, due to potential interactions between atorvastatin and HIV protease inhibitors, 11. History of solid organ transplant, due to potential interactions between atorvastatin and immunosuppressants 12. Active cancer, or 13. Current use of medications with potential drug interactions, namely cyclosporine, clarithromycin, itraconazole, HIV protease inhibitors, rifampin, and digoxin.

Inclusion Criteria: * Adult patient * Patient who has received adjuvant ABEMACICLIB in combination with hormone therapy * Patient with localized RH+ HER2 non-amplified breast cancer and eligible for treatment with ABEMACICLIB according to the recommendations of the MA (Marketing Authorization) as defined below: * 4 ipsilateral positive axillary lymph nodes OR 1. to 3 ipsilateral positive axillary lymph node(s) with at least one of the following two criteria: histological grade 3 or primary tumor size ≥5 cm Exclusion Criteria: * Patients under legal protection (guardianship, trusteeship, etc.) * Refusal to participate

Inclusion Criteria: * Both male and female adults aged 18-45 years. * Participants lying in Low PA (inactive) category on basis of IPAQ. * Pre-hypertensive adults: * SBP- 120 mmHg or more and \<140 mmHg * DBP of 80 mmHg or more and \< 90 mmHg. * Normotensive adults: SBP \< 120 mmHg and DBP \< 80 mmHg. Exclusion Criteria * Diagnosed with any current infections. * Subjects with any diagnosed cardiovascular or respiratory conditions. * Subjects with diagnosed musculoskeletal or neurological conditions which hinder participation in physical activity program. * Active Smokers * Those with any contraindication to exercise testing or training. * Pregnant females

Inclusion Criteria: 1. Males and females ages 22-64, inclusive 2. Diagnosis: Bipolar I disorder confirmed by SCID-5, currently in a major depressive episode (MDE). 3. Symptom Severity: MADRS score of ≥27 at Screening and pre-operative baseline visit. CGI-S \> 4 and YMRS \<12 at these visits. 4. Failure to respond or maintain a response to a minimum of four evidence-based interventions for bipolar depression in the patient's lifetime, including at least two FDA-approved medications (olanzapine/fluoxetine, quetiapine, lurasidone, cariprazine, lumateperone), or ECT, administered at adequate doses and duration (adequately defined by the Antidepressant Treatment History Form (ATHF-Short Form). During the current episode, the patient must have failed to respond or maintain a response to a minimum of two FDA-approved interventions for bipolar depression. In addition, the patient is required to be currently taking at least one evidence-based medication for bipolar disorder (e.g., lithium, either alone or in combination with an atypical antipsychotic such as quetiapine), unless no evidence-based medications for bipolar disorder are tolerated. 5. Initial mood episode occurred before the age of 40 - to minimize risk of enrolling patients with so atypical onset of initial mania/depression. 6. Must be on a stable dose of psychotropic medications for a minimum of four weeks prior to surgery. 7. Minimum score on the Montreal Cognitive Assessment (MoCA). 8. Able and willing to give informed consent and sign Treatment Contract that includes identification of a reliable informant. Exclusion Criteria: 1. Lifetime history of a psychotic disorder (e.g., schizophrenia, schizoaffective disorder, and other psychotic disorders), or any history of psychotic symptoms when not in a bipolar mood episode. 2. Currently meets criteria for a manic or hypomanic episode or rapid cycling (4 or more mood episodes in the previous 12 months). 3. Any psychiatric disorder which is the primary focus of treatment within the past 12 months (with bipolar disorder as the secondary focus of treatment). 4. Alcohol/substance use disorder, moderate or severe, within the previous 12 months \[excluding nicotine\]. 5. Intellectual disability or neurocognitive disorder. 6. Current major and/or unstable medical conditions. e.g., liver insufficiency, kidney insufficiency, cardiovascular problems \[unstable arrhythmias, chronic heart failure, myocardial infarction (MI), cardiac pacemaker\], systemic infections, cancer, active upper respiratory infections, endocrinopathies, and any major neurological disorder \[e.g., seizure disorder, stroke, dementia, degenerative neurologic diseases, traumatic brain injury\]. 7. Any medical contraindication to surgery or condition that makes the patient, in the opinion of the surgeon, a poor candidate. 8. Female who is pregnant or breastfeeding or has plans to become pregnant in the next 24 months. 9. Any contraindication for MRI. 10. Patients with a clinically significant personality disorder, including risk for homicidal or aggressive behavior, which in the opinion of the investigator has a major impact on the patient's current psychiatric status and/or would preclude safe study participation. 11. Patients at serious and imminent risk of suicide and not suitable for an outpatient study, in the judgment of the investigators. 12. Participation in any investigational clinical trial within the preceding 30 days. 13. Current implanted stimulation devices including cardiac pacemakers, defibrillators, and neurostimulators \[including deep brain and spinal cord stimulators\]. 14. Patients with no regular contact with at least one adult. Patients who are undomiciled are excluded. 15. Body mass index (BMI) less than 16 and greater than 40 kg/m2 16. Need for diathermy. 17. Unable to sign the informed consent for any reason. 18. Patients who are not under the care of a psychiatrist at Screening and throughout the duration of the study.

Inclusion Criteria: * Inclusion criteria are patients aged ≥ 18 years old； * Patients diagnosed with PH based on right ventricular systolic pressure (RVSP)\>50 mmHg on echocardiography or right heart catheterization (resting mean pulmonary artery pressure ≥ 25 mmHg)； * And patients who require HFNC or NIV respiratory support after ACRF (defined as acute deterioration of respiratory function in patients with chronic respiratory diseases, resulting in PaO2\<60 mmHg, PaO2/FiO2 ratio\<300 mmHg, or respiratory rate\>30 breaths per minute in indoor air). Exclusion Criteria: * The exclusion criteria were patients with acute coronary syndrome, acute myocardial infarction, severe arrhythmias, severe cerebrovascular or neurological diseases, and severe hepatic or renal dysfunction; * those who were receiving endotracheal intubation or NIV within 24 h of admission; * patients who were not intubated; * those who were receiving palliative care; * immunocompromised patients; * patients with incomplete data or who were lost to follow-up.

Inclusion Criteria: * Aged 18 years old and above. * Diagnosis of Type 2 diabetes. * Receiving and monitoring diabetes care from diabetes center. * With stable HbA1c less than 10% (no episode of hypoglycaemia, no hospitalisation, no change in type or dosage of medication use for at least 6 months). Exclusion Criteria: * Pregnant or lactating women. * Diagnosis of cardiac failure or/and severe renal disease, with physical or mental disability, neurological or cognitive impairment. * Participant with severely impaired vision, hearing, or speech. * Participants who have known allergy to dates products.

Inclusion Criteria: * Diagnosis of oncological disease in the last 5 years * Diagnosis of Major Depressive Disorder, without psychotic symptoms, according to DSM-5 criteria * 17-item Hamilton Rating Scale for Depression (HAM-D-17) (score ≥14) * Age: 18 years or older * Oncological disease in a non-advanced stage (Karnofsky Performance Status \> 80) Exclusion Criteria: * Current or prior hospitalization in the next 6 months * Planned surgery in the next 6 months * Suicidal ideation * Substance use * History of significant head trauma, neurological disorders, intellectual deficits * Recurrent seizures resulting from head trauma or conditions lowering seizure threshold * Concurrent use of medications that increase the risk of epileptic seizures (e.g., antipsychotics, tricyclics, theophylline) * Glaucoma, retinal detachment, or other serious vision impairments that may prevent the use of virtual reality technology * Severe problems with autonomous ambulation

Inclusion Criteria: Schools: * Have been trained in either Tealeaf or RE-SEED in Summer 2024 or 2025 after being randomized programmatically * Be a school in the State of North Carolina * Have an eligible principal Principals: * \>18 years old * Employed at an enrolled school * Not suspected or convicted of child-related misconduct or maltreatment Teachers: * \>18 years old * Employed at an enrolled school * Primary teaching responsibility for a single academic class (for a minimum of 1 hour per day and a minimum of 4 days per week) in any grade level Kindergarten to Grade 8 * Not suspected or convicted of child-related misconduct or maltreatment Counselors: * \>18 years old * Employed at an enrolled school * Hold a school counselor position at an enrolled school for at least 10 hours per week * Not suspected or convicted of child-related misconduct or maltreatment Students: * Enrolled in Kindergarten-Grade 8 * Student of an enrolled teacher * Has a parent or guardian who can provide consent * Positive/Clinical-level score on the Strengths and Difficulties Questionnaire (SDQ) Guardians: * \>18 years old * Guardian of enrolled student Exclusion Criteria: * Exclusion criteria will be set as each participant does not meet the inclusion criteria as set for their group.

Inclusion Criteria: * Asthmatic Patients, should take inhalers regularly for at least 3 months and come personally for re-fill. Exclusion Criteria: * Coexistence of other chronic respiratory conditions. * Those who were difficult to communicate.

Inclusion Participants must meet all the following criteria to be eligible for randomization into the study: 1. Sign and date the informed consent form prior to the start of any study-specific qualification procedures. 2. Female aged ≥18 years. 3. Has ECOG PS of ≤1. 4. Life expectancy ≥ 3months. 5. Histological or cytological confirmation of triple-negative breast cancer (TNBC). 6. At least one prior chemotherapy regimen with anthracyclines and taxanes for advanced disease. 7. Has at least 1 measurable brain metastatic lesion according to RANO-BM. 8. Adequate biological function. 9. Men or women should be using adequate contraceptive measures during the study and for 6 months following the last dose of investigational product. Exclusion Participants who meet any of the following criteria will be disqualified from entering the study: 1. Patients who have received prior anti-cancer treatment within 4 weeks. 2. . Patients must not have previously received JK-1201I or any other form of irinotecan, SN38. 3. Hypersensitivity to any ingredient of JK-1201I and Topotecan. 4. Current use or any use in the last two weeks of strong CYP3A-enzyme inducers / in the last two weeks of strong CYP3A-enzyme inhibitors and / or strong UGT1A inhibitors. 5. Unresolved toxicity from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 1 with exceptions defined in the protocol. 6. History of other malignancies within last 5 years. 7. History of immunodeficiency disease, or positive human immunodeficiency virus antibody. 8. Severe infections within 4 weeks before the first use of the study drug. 9. Active hepatitis B virus infection, or active hepatitis C virus infection. 10. Patients who received surgery within last 4 weeks before the initiation of study treatment. 11. Patients with brain stem, meningeal or spinal cord metastasis. 12. Severe symptoms by tumor aggressive important organ. 13. Uncontrolled hydrothorax and ascites. 14. Uncontrolled concomitant systemic disorder as defined in the protocol. 15. Serious cardiac condition or uncontrolled high blood pressure. 16. History of mental illness, drug abuse, alcoholism. 17. Pregnant or breast-feeding. 18. Other conditions that the investigator considers unsuitable to participate in this clinical trial.

Inclusion Criteria: * 18 to 59 years old * body mass index ≥30.0 kg/m2 and \<45.0 kg/m2 Additional, group-specific inclusion criteria: * Family history of type 2 diabetes: first degree relative with type 2 diabetes * Control group: no family history of type 2 diabetes Exclusion Criteria: * Pregnant, planning to become pregnant during the study, or breastfeeding * Current diagnosis or history of type 1 or type 2 diabetes * Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists) * History of bariatric surgery * Known, uncontrolled hypothyroidism * History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment * Current cancer or cancer that has been in remission less than 5 years * First degree relative with type 1 diabetes diagnosis * Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease) * Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day * Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration * Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent

Inclusion Criteria: * Followed in one of the NexusHealth hospitals in Belgium: https://www.nexuzhealth.com/en/why-nexuzhealth/patients/affiliated-healthcare-institutions * Having being diagnosed with type 2 diabetes mellitus * Followed in the Diabetes Care Trajectory or in the Diabetes Convention (group B) in Belgium Exclusion Criteria: no specific exclusion criteria

Inclusion Criteria: * Age \> 18 years, no gender restrictions; * Primary refractory hypertension: Taking three antihypertensive drugs, including a - diuretic, with an average office systolic blood pressure ≥150 mmHg measured three times; * Duration of hypertension greater than 6 months; * Standing plasma aldosterone and renin activity not below the lower limit of the unit's reference range; * Signed informed consent form. Exclusion Criteria: * Morning cortisol level \< 4.3 µg/dL; estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73 m²; serum potassium level \> 5.5 mmol/L; * Type 1 diabetes, uncontrolled hyperthyroidism, malignant arrhythmias, malignant tumors, decompensated heart failure, severe liver dysfunction, severe hematological diseases, severe obstructive sleep apnea syndrome, history of myocardial infarction, syncope, cerebral hemorrhage, or cerebral infarction within the past 3 months; * Pregnant women or those planning to conceive within the next year; * Presence of other severe organic diseases that would make the patient unable to tolerate superselective adrenal arterial embolization; * Adrenal mass with a diameter exceeding 2 cm; * Severe allergy to contrast agents; * Patients enrolled or planning to participate in other clinical studies that could impact the results of this study.

Inclusion Criteria: * Age ≥60 years * Previously diagnosed with early-stage (I-III) BC * Completed (≥1 year post) primary cardiotoxic treatment (anthracycline-based chemotherapy or trastuzumab-based biological therapy). Exclusion Criteria: * Have a history of coronary artery disease, heart failure, persistent and permanent arrhythmia (e.g. currently in atrial fibrillation), stroke, or chronic obstructive pulmonary disease * Develop signs or symptoms of myocardial ischemia (≥1mm horizontal or down-sloping ST segment depression on electrocardiogram) during the cardiopulmonary (VO2peak) test * Have any research MRI contraindications (e.g. any type of pacemaker), or any orthopedic limitation preventing exercise testing * Currently performing structured exercise training (defined as ≥30 mins/day of moderate-to-vigorous aerobic and/or resistance exercise training on ≥4 days/week) * Are unwilling to be randomized to either ExT or STRETCH

Inclusion Criteria: * 18 years or older; * Provided written informed consent; * Undergoing controlled mechanical ventilation via an endotracheal tube; * Reason for intubation being exacerbation of asthma or COPD; * Intubated ≤72 hours Exclusion Criteria: * Severe sputum stasis or production requiring frequent bronchial suctioning (more than 5 times per nurse shift) * Untreated pneumothorax (i.e. no pleural drainage) * Hemodynamic instability defined as a mean arterial pressure below 60mmHg not responding to fluids and/or vasopressors or a noradrenalin dose \>0.5mcrg/kg/min * High (\>15 mmHg) or instable (an increase in sedation or osmotherapy is required) intracranial pressure * An inner tube diameter of 6mm or less * Anticipating withdrawal of life support and/or shift to palliation as the goal of care * Inability to perform adequate electrical impedance tomography (EIT) measurements with, e.g.: * Have a thorax circumference inappropriate for EIT-belt * Thoracic wounds, bandages or deformities preventing adequate fit of EIT-belt * Recent (\<7 days) pulmonary surgery including pneumonectomy, lobectomy or lung transplantation * ICD device present (potential interference with proper functioning of the EIT device and ICD device) * Excessive subcutaneous emphysema * Contra-indications for nasogastric tube or inability to perform adequate transpulmonary pressure measurements with, e.g.: * Recent esophageal surgery * Prior esophagectomy * Known presence of esophageal varices * Severe bleeding disorders

Inclusion Criteria: 1. Adult patients older than 40 years of age. 2. Diagnosis of Type 2 Diabetes Mellitus (insulin dependent or non-insulin dependent) for at least 5 years. 3. Diagnosis of Cardiovascular Disease (Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease, etc…) --OR-- Have one (1) of the following concomitant medical diagnoses: 1. Diabetic Retinopathy (proliferative or non-proliferative) 2. Diabetic Nephropathy (eGFR \&lt;60 mL/min/1.73m2 and/or urine albumin/creatinine ratio ≥30 mg/g) 3. Diabetic Neuropathy 4. Elevated High-sensitivity C-reactive protein (hs-CRP) --AND-- Have a history of two (2) or more of the following: 5. Diagnosis of Hypertension for at least 6 months or more (treated or untreated) 6. Hypercholesterolemia (LDL-C \&gt;100 mg/dL) 7. Obesity (Body Mass Index (BMI) ≥ 27 for men or ≥ 22 for women) 8. History of Smoking 4. Willingness to undergo HEMOTAG evaluation. 5. Willingness to undergo Standard of Care visits/assessments and NT-pro BNP lab evaluations. 6. Willingness to conduct at-home HEMOTAG evaluations at least three days per week within a 30-day time period after the completion of the Baseline Visit, after the 6 month visit and following discharge from any hospitalizations due to a cardiac events during the 12 month study period. 7. Willingness to receive and return shipping of the HEMOTAG KIT at each time point as required by the protocol 8. Able to give informed consent. Exclusion Criteria: 1. Terminal condition with life expectancy less than 12 months as determined by investigator. 2. Physical deformity in the chest area or lesion that may prevent proper HEMOTAG application or adjustment. 3. Illness/ Condition which may be aggravated or cause significant discomfort to the patient by the application of the HEMOTAG (skin issues, e.g. Intolerance to use of skin electrodes). 4. Participant enrolled in another interventional study (observational or registries are not excluded). 5. Prisoners and wards of the state. 6. Impaired cognitive ability or any other state that may prevent full compliance with the study protocol, according to investigator\&#39;s assessment. 7. Participants unable to provide informed, voluntary decision to participate in research study as determined by the investigator. (Exclude participants who necessitate the involvement of a legally authorized representative.) 8. Inability to provide informed consent (Must speak English). 9. Women who are pregnant or are planning to become pregnant during the study. 10. Women of childbearing potential who are unwilling or unable to comply with contraception measures.